Athira Pharma, Inc. (ATHA)
- Previous Close
1.9200 - Open
1.9200 - Bid 1.9100 x 400
- Ask 1.9400 x 300
- Day's Range
1.9100 - 2.0100 - 52 Week Range
1.3300 - 4.2980 - Volume
164,543 - Avg. Volume
352,409 - Market Cap (intraday)
73.587M - Beta (5Y Monthly) 2.78
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0900 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.42
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
www.athira.comRecent News: ATHA
Performance Overview: ATHA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATHA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATHA
Valuation Measures
Market Cap
73.59M
Enterprise Value
-72.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.57
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.57
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.97%
Return on Equity (ttm)
-64.42%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-117.67M
Diluted EPS (ttm)
-3.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
147.42M
Total Debt/Equity (mrq)
1.22%
Levered Free Cash Flow (ttm)
-60.9M
Research Analysis: ATHA
Company Insights: ATHA
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: ATHA
Daily – Vickers Top Buyers & Sellers for 06/07/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/03/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/07/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/04/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.